These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37957561)

  • 41. Stronger Association of Albuminuria with the Risk of Vascular Complications than Estimated Glomerular Filtration Rate in Type 2 Diabetes.
    Hong X; Huang L; Zhang Y; Shen X; Weng S; Zeng F; Zhao F; Yan S
    Kidney Blood Press Res; 2021; 46(5):550-562. PubMed ID: 34428770
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
    Tanaka A; Shibata H; Imai T; Yoshida H; Miyazono M; Takahashi N; Fukuda D; Okada Y; Teragawa H; Suwa S; Kida K; Moroi M; Taguchi I; Toyoda S; Shimabukuro M; Tanabe K; Tanaka K; Nangaku M; Node K;
    Cardiovasc Diabetol; 2023 Jul; 22(1):194. PubMed ID: 37525257
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence and risk factors for chronic kidney disease in primary health care in the southern region of New Zealand.
    Lloyd H; Li G; Tomlin A; Tilyard MW; Walker R; Schollum J
    Nephrology (Carlton); 2019 Mar; 24(3):308-315. PubMed ID: 29717528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
    Rossing P; Burgess E; Agarwal R; Anker SD; Filippatos G; Pitt B; Ruilope LM; Gillard P; MacIsaac RJ; Wainstein J; Joseph A; Brinker M; Roessig L; Scott C; Bakris GL;
    Diabetes Care; 2022 Apr; 45(4):888-897. PubMed ID: 35061867
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
    Neuen BL; Ohkuma T; Neal B; Matthews DR; de Zeeuw D; Mahaffey KW; Fulcher G; Blais J; Li Q; Jardine MJ; Perkovic V; Wheeler DC
    Am J Kidney Dis; 2021 Jan; 77(1):23-34.e1. PubMed ID: 32971190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevalence rates of chronic kidney disease and its association with cardiometabolic factors and cardiovascular diseases. SIMETAP-CKD study.
    Ruiz-Garcia A; Arranz-Martínez E; Iturmendi-Martínez N; Fernández-Vicente T; Rivera-Teijido M; García-Álvarez JC
    Clin Investig Arterioscler; 2023; 35(2):64-74. PubMed ID: 35945036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice.
    van der Meer V; Wielders HP; Grootendorst DC; de Kanter JS; Sijpkens YW; Assendelft WJ; Gussekloo J; Dekker FW; Groeneveld Y
    Br J Gen Pract; 2010 Dec; 60(581):884-90. PubMed ID: 21144198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Grams ME; Yang W; Rebholz CM; Wang X; Porter AC; Inker LA; Horwitz E; Sondheimer JH; Hamm LL; He J; Weir MR; Jaar BG; Shafi T; Appel LJ; Hsu CY;
    Am J Kidney Dis; 2017 Sep; 70(3):337-346. PubMed ID: 28366517
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
    Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
    BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Bariatric Surgery on Diagnosed Chronic Kidney Disease and Cardiovascular Events in Patients with Insulin-treated Type 2 Diabetes: a Retrospective Cohort Study from a Large UK Primary Care Database.
    Alkharaiji M; Anyanwagu U; Donnelly R; Idris I
    Obes Surg; 2020 May; 30(5):1685-1695. PubMed ID: 32130651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute and chronic complication profiles among patients with chronic kidney disease in Alberta, Canada: a retrospective observational study.
    Lau DCW; Shaw E; McMullen S; Cowling T; Witges K; Amitay EL; Steubl D; Girard LP
    BMC Nephrol; 2024 Jul; 25(1):244. PubMed ID: 39080608
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incidence and Progression of Chronic Kidney Disease in Black and White Individuals with Type 2 Diabetes.
    Gerber C; Cai X; Lee J; Craven T; Scialla J; Souma N; Srivastava A; Mehta R; Paluch A; Hodakowski A; Frazier R; Carnethon MR; Wolf MS; Isakova T
    Clin J Am Soc Nephrol; 2018 Jun; 13(6):884-892. PubMed ID: 29798889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sex differences in hypertension-related renal and cardiovascular diseases in Italy: the I-DEMAND study.
    Muiesan ML; Ambrosioni E; Costa FV; Leonetti G; Pessina AC; Salvetti M; Trimarco B; Volpe M; Pontremoli R; Deferrari G; Rosei EA
    J Hypertens; 2012 Dec; 30(12):2378-86. PubMed ID: 23137952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
    Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
    Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria.
    McGill JB; Haller H; Roy-Chaudhury P; Cherrington A; Wada T; Wanner C; Ji L; Rossing P
    BMJ Open Diabetes Res Care; 2022 Jul; 10(4):. PubMed ID: 35790319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.